Špela Volčanšek
YOU?
Author Swipe
View article: Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Open
View article: Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies Open
View article: Health-Related Quality of Life Assessment in Older Patients with Type 1 and Type 2 Diabetes
Health-Related Quality of Life Assessment in Older Patients with Type 1 and Type 2 Diabetes Open
Type 1 (T1D) and type 2 diabetes (T2D) are determinants of health-related outcomes including health-related quality of life (HRQOL). We aimed to determine differences in HRQOL between older adults with T1D and T2D and specific factors infl…
View article: The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials Open
Type 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications…
View article: No Indices of Increased Type 2 Diabetes Risk in Individuals with Reactive Postprandial Hypoglycemia
No Indices of Increased Type 2 Diabetes Risk in Individuals with Reactive Postprandial Hypoglycemia Open
Reactive postprandial hypoglycemia (RPH) is an understudied condition that lacks clinical definition, knowledge of future health implications, and an understanding of precise underlying mechanisms. Therefore, our study aimed to assess the …
View article: Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence Open
The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardi…
View article: Inzulinska rezistenca v perioperativnem obdobju – temelj večdisciplinarnih pobud za pospešeno okrevanje po posegu v srčnožilni kirurgiji
Inzulinska rezistenca v perioperativnem obdobju – temelj večdisciplinarnih pobud za pospešeno okrevanje po posegu v srčnožilni kirurgiji Open
Inzulinska rezistenca oziroma stanje zmanjšanega biološkega odziva na fiziološke ravni inzulina je ključni dejavnik tveganja za srčnožilne bolezni, zato je pogosto prisotna pri bolnikih v srčnožilni kirurgiji. Vnetni procesi, poškodba tkiv…
View article: Problematika uživanja pijač z dodanim sladkorjem v Sloveniji in svetu
Problematika uživanja pijač z dodanim sladkorjem v Sloveniji in svetu Open
Pojavnost kardiometabolnih bolezni je dosegla pandemične razsežnosti, zato se čedalje večja pozornost posveča tudi z življenjskim slogom pogojenemu zdravju prebivalstva, še posebej načinu prehranjevanja in vnosu določenih skupin živil. Šte…
View article: Metformin: od mehanizmov delovanja do napredne klinične uporabe
Metformin: od mehanizmov delovanja do napredne klinične uporabe Open
Metformin represents the first line of treatment and is the most widely prescribed antihypergycemic drug in type 2 diabetic patients. It can be used as monotherapy or in combination with other oral antihyperglycemic drugs or insulin. Addit…
View article: Metformin: from mechanisms of action to advanced clinical use
Metformin: from mechanisms of action to advanced clinical use Open
Metformin represents the first line of treatment and is the most widely prescribed antihypergycemic drug in type 2 diabetic patients. It can be used as monotherapy or in combination with other oral antihyperglycemic drugs or insulin. Addit…